Volume 82, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



West Nile virus (WNV) causes serious neurologic disease, but no licensed vaccines are available to prevent this disease in humans. We have developed RepliVAX WN, a single-cycle flavivirus with an expected safety profile superior to other types of live-attenuated viral vaccines. In this report we describe studies examining RepliVAX WN safety, potency, and efficacy in a non-human primate model of WNV infection. A single immunization of four rhesus macaques with RepliVAX WN was safe and elicited detectable neutralizing antibody titers and IgM and IgG responses, and IgG titers were increased in two animals that received a second immunization. After challenge with WNV, three of four immunized animals were completely protected from viremia, and the remaining animal showed minimal viremia on one day. In contrast, the unvaccinated animal developed viremia that lasted six days. These results demonstrate the efficacy and safety of RepliVAX WN in this primate model of WNV infection.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Centers for Disease Control and Prevention, 2009. West Nile Virus - Statistics, Surveillance, and Control - Case Count 2008. Available at: http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount08_detailed.htm. Accessed May 20, 2009. [Google Scholar]
  2. Davis BS, Chang GJJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML, , 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75: 40404047.[Crossref] [Google Scholar]
  3. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ, , 2003. Equine vaccine for West Nile virus. Dev Biol (Basel) 114: 221227. [Google Scholar]
  4. Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B, , 2004. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl: 221230. [Google Scholar]
  5. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, Andrews CA, Xu Q, Davis BS, Nason M, Fay M, Koup RA, Roederer M, Bailer RT, Gomez PL, Mascola JR, Chang GJ, Nabel GJ, Graham BS, , 2007. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196: 17321740.[Crossref] [Google Scholar]
  6. Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P, , 2006. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103: 66946699.[Crossref] [Google Scholar]
  7. Watts DM, Tesh RB, Siirin M, Rosa AT, Newman PC, Clements DE, Ogata S, Coller BA, Weeks-Levy C, Lieberman MM, , 2007. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 25: 29132918.[Crossref] [Google Scholar]
  8. Konishi E, Mason PW, , 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol 67: 16721675. [Google Scholar]
  9. Mason PW, Pincus S, Fournier MJ, Mason TL, Shope RE, Paoletti E, , 1991. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology 180: 294305.[Crossref] [Google Scholar]
  10. Konishi E, Pincus S, Paoletti E, Shope RE, Burrage T, Mason PW, , 1992. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188: 714720.[Crossref] [Google Scholar]
  11. Qiao M, Ashok M, Bernard KA, Palacios G, Zhou ZH, Lipkin WI, Liang TJ, , 2004. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis 190: 21042108.[Crossref] [Google Scholar]
  12. Aberle JH, Aberle SW, Allison SL, Stiasny K, Ecker M, Mandl CW, Berger R, Heinz FX, , 1999. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. J Immunol 163: 67566761. [Google Scholar]
  13. Konishi E, Yamaoka M, Kurane I, Mason PW, , 2000. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18: 11331139.[Crossref] [Google Scholar]
  14. Mason PW, Shustov AV, Frolov I, , 2006. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 351: 432443.[Crossref] [Google Scholar]
  15. Widman DG, Ishikawa T, Fayzulin R, Bourne N, Mason PW, , 2008. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 26: 27622771.[Crossref] [Google Scholar]
  16. Widman DG, Ishikawa T, Winkelmann ER, Infante E, Bourne N, Mason PW, , 2009. RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 27: 55505553.[Crossref] [Google Scholar]
  17. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, Kotchasenee S, Gingrich JB, Latendresse J, Fukai K, , 1988. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319: 608614.[Crossref] [Google Scholar]
  18. Halstead SB, Tsai TF, Plotkin S, Orenstein WA, , 2004. Japanese encephalitis vaccine. , eds. Vaccine. Philadelphia: W.B. Saunders Company, 919957. [Google Scholar]
  19. World Health Organization, 1998. Japanese encephalitis vaccines. Wkly Epidemiol Rec 73: 337344. [Google Scholar]
  20. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB, , 2001. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 7: 714721.[Crossref] [Google Scholar]
  21. Bourne N, Scholle F, Silva MC, Rossi SL, Dewsbury N, Judy B, De Aguiar JB, Leon MA, Estes DM, Fayzulin R, Mason PW, , 2007. Early production of type i interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J Virol 81: 91009108.[Crossref] [Google Scholar]
  22. Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, Barrett ADT, Nichols R, Weltzin R, Arroyo J, Guirakhoo F, , 2000. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 74: 17421751.[Crossref] [Google Scholar]
  23. Clarke DH, Casals J, , 1958. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7: 561573. [Google Scholar]
  24. Caul EO, Smyth GW, Clarke SK, , 1974. A simplified method for the detection of rubella-specific IgM employing sucrose density fractionation and 2-mercaptoethanol. J Hyg (Lond) 73: 329340.[Crossref] [Google Scholar]
  25. Ratterree MS, Gutierrez RA, Travassos da Rosa AP, Dille BJ, Beasley DW, Bohm RP, Desai SM, Didier PJ, Bikenmeyer LG, Dawson GJ, Leary TP, Schochetman G, Phillippi-Falkenstein K, Arroyo J, Barrett AD, Tesh RB, , 2004. Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis 189: 669676.[Crossref] [Google Scholar]
  26. Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, Monath TP, , 2004. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78: 1249712507.[Crossref] [Google Scholar]
  27. Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR, , 2006. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24: 63926404.[Crossref] [Google Scholar]
  28. Shrestha B, Ng T, Chu HJ, Noll M, Diamond MS, , 2008. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26: 20202033.[Crossref] [Google Scholar]
  29. Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett AD, , 2004. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22: 37223726.[Crossref] [Google Scholar]
  30. Shrestha B, Diamond MS, , 2004. Role of CD8+ T cells in control of West Nile virus infection. J Virol 78: 83128321.[Crossref] [Google Scholar]
  31. Kreil TR, Maier E, Fraiss S, Eibl MM, , 1998. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J Virol 72: 30763081. [Google Scholar]
  32. Barrett PN, Schober-Bendixen S, Ehrlich HJ, , 2003. History of TBE vaccines. Vaccine 21 (Suppl 1): S41S49.[Crossref] [Google Scholar]
  33. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, , 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533541. [Google Scholar]
  34. Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM, , 2003. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 314: 190195.[Crossref] [Google Scholar]
  35. Silva MC, Guerrero-Plata A, Gilfoy FD, Garofalo RP, Mason PW, , 2007. Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J Virol 81: 1364013648.[Crossref] [Google Scholar]

Data & Media loading...

Supplementary Figure

Supplementary Table

  • Received : 04 Jun 2009
  • Accepted : 12 Feb 2010
  • Published online : 04 Jun 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error